Freenome co-founder Riley Ennis. Photo credit: Diarmuid Greene / Collision / Sportsfile, under Creative Commons license

Freenome, a South San Francisco-based cancer detection upstart, has raised $270 million in Series C financing led by Bain Capital Life Sciences and Perceptive Advisors, a biotech-focused hedge fund. Other participants in the round include the likes of Andreessen Horowitz, Alphabet’s GV, Kaiser Permanente Ventures, Fidelity, and pharmaceutical giants Roche and Novartis. The new investment brings the total amount of funding that Freenome, a six-year-old company, has raised since its inception to over $500 million.

Freenome will put the new capital towards expanding its operations, which is primarily developing blood tests for detecting certain types of cancers. Mainly, the new funding will be put towards accelerating Freenome’s trial of a blood test for colorectal cancer screening. Freenome is currently working on trials for that test in hopes of an FDA approval.

Under the terms of the new financing, Ellen Hukkelhoven, a Managing Director at Perceptive Advisors, will join Freenome’s board.